Now available nationwide. Horse owners are encouraged to contact their veterinarian.
Schaumburg, IL — [MAY 5, 2026] — Bimeda® a global leader in animal health solutions, today announced the U.S. launch of GASTROBIM™ (omeprazole), the first and only FDA-approved bioequivalent to GastroGard® (omeprazole) for the treatment and prevention of recurrence of gastric ulcers in horses and foals four weeks of age and older. This apple-flavored formulation offers veterinarians, trainers, and horse owners a clinically equivalent, high-quality alternative for the effective management of Equine Gastric Ulcer Syndrome (EGUS), addressing a critical need in equine health.
Since its initial launch in 2024, GASTROBIM™ has rapidly emerged as the fastest-growing omeprazole product in Canada and Europe. Its strong adoption and positive reception among veterinarians and horse owners underscore its proven efficacy in treating and healing gastric ulcers, reinforcing its position as a trusted therapeutic option worldwide. The introduction of GASTROBIM™ in the U.S. further expands Bimeda's established equine portfolio, which includes leading brands such as EquiMAX® (1.87% ivermectin 14.03% praziquantel), PolyglycanTM (hyaluronic acid + chondroitin sulfates C4 & C6 + N-acetyl-D-glucosamine sterile solution), Detomequin® (detomidine hydrochloride), and Bimectin® (ivermectin paste), and reflects the company's ongoing commitment to delivering innovative, reliable solutions to the equine industry.
"We are thrilled to introduce GASTROBIM™ to the U.S. market," said Eric Moore, DVM, Bimeda's Head of Technical Services North America. "Gastric ulcers remain one of the most common and performance limiting conditions in horses. Offering a bioequivalent, rigorously tested treatment underscores our commitment to supporting equine health, welfare, and performance at an affordable price."
Equine Gastric Ulcer Syndrome (EGUS) affects a significant percentage of performance horses, often leading to reduced appetite, behavioral changes, discomfort, and decreased athletic performance. By introducing a bioequivalent, apple-flavored alternative, Bimeda aims to broaden access to effective treatment options and support improved health and performance outcomes across the equine industry.
About Bimeda
Bimeda® is a global leader in the development, manufacturing, and distribution of animal health products and veterinary pharmaceuticals. Dedicated to delivering high-quality, customer-focused solutions at competitive price points.
Through continued growth and strategic acquisitions, Bimeda® has established a presence in more than 80 countries, supported by robust research and development, manufacturing, and distribution capabilities across Europe, North America, Latin America, Africa, Asia, and Australia. With a global workforce of over 1,200 employees headquartered in Dublin, Ireland, Bimeda remains committed to optimizing the health and wellbeing of animals around the world.
GASTROBIM™ is now available nationwide. For more information, visit www.gastrobim.com or contact your veterinarian.